尿失禁治療薬の世界市場2019-2023...市場調査レポートについてご紹介

【英文タイトル】Global Urinary Incontinence Therapeutics Market 2019-2023

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 04: MARKET SIZING
• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 06: MARKET SEGMENTATION BY PRODUCT
• Market segmentation by product
• Comparison by product
• Anticholinergic drugs – Market size and forecast 2018-2023
• Others – Market size and forecast 2018-2023
• Market opportunity by product
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• Americas – Market size and forecast 2018-2023
• EMEA – Market size and forecast 2018-2023
• APAC – Market size and forecast 2018-2023
• Key leading countries
• Market opportunity
PART 09: DECISION FRAMEWORK
PART 10: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 11: MARKET TRENDS
PART 12: VENDOR LANDSCAPE
• Overview
• Landscape disruption
PART 13: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• ALLERGAN
• Astellas Pharma
• Merck
• Novartis
• Pfizer
PART 14: APPENDIX
• Research methodology
• List of abbreviations
PART 15: EXPLORE TECHNAVIO


Exhibit 01: Global CNS therapeutics market
Exhibit 02: Segments of global CNS therapeutics market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition – Inclusions and exclusions checklist
Exhibit 06: Market size 2018
Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 09: Five forces analysis 2018
Exhibit 10: Five forces analysis 2023
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition – Five forces 2018
Exhibit 17: Product – Market share 2018-2023 (%)
Exhibit 18: Comparison by product
Exhibit 19: MoA of anticholinergic drugs
Exhibit 20: Anticholinergic drugs – Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Anticholinergic drugs – Year-over-year growth 2019-2023 (%)
Exhibit 22: Others – Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Others – Year-over-year growth 2019-2023 (%)
Exhibit 24: Market opportunity by product
Exhibit 25: Customer landscape
Exhibit 26: Market share by geography 2018-2023 (%)
Exhibit 27: Geographic comparison
Exhibit 28: Americas – Market size and forecast 2018-2023 ($ millions)
Exhibit 29: Growth in geriatric population in various countries of Americas 2007 and 2017 (%)
Exhibit 30: Americas – Year-over-year growth 2019-2023 (%)
Exhibit 31: Top 3 countries in Americas
Exhibit 32: EMEA – Market size and forecast 2018-2023 ($ millions)
Exhibit 33: EMEA – Year-over-year growth 2019-2023 (%)
Exhibit 34: Top 3 countries in EMEA
Exhibit 35: APAC – Market size and forecast 2018-2023 ($ millions)
Exhibit 36: APAC – Year-over-year growth 2019-2023 (%)
Exhibit 37: Top 3 countries in APAC
Exhibit 38: Key leading countries
Exhibit 39: Market opportunity
Exhibit 40: Prevalence, rate of urinary incontinence among the US residential care facility residents aged 65 and over 2010 (%)
Exhibit 41: Recent approvals of generic drugs
Exhibit 42: Impact of drivers and challenges
Exhibit 43: Vendor landscape
Exhibit 44: Landscape disruption
Exhibit 45: Vendors covered
Exhibit 46: Vendor classification
Exhibit 47: Market positioning of vendors
Exhibit 48: ALLERGAN – Vendor overview
Exhibit 49: ALLERGAN – Business segments
Exhibit 50: ALLERGAN – Organizational developments
Exhibit 51: ALLERGAN – Geographic focus
Exhibit 52: ALLERGAN – Segment focus
Exhibit 53: ALLERGAN – Key offerings
Exhibit 54: ALLERGAN – Key customers
Exhibit 55: Astellas Pharma – Vendor overview
Exhibit 56: Astellas Pharma – Business segments
Exhibit 57: Astellas Pharma – Organizational developments
Exhibit 58: Astellas Pharma – Geographic focus
Exhibit 59: Astellas Pharma – Segment focus
Exhibit 60: Astellas Pharma – Key offerings
Exhibit 61: Astellas Pharma – Key customers
Exhibit 62: Merck – Vendor overview
Exhibit 63: Merck – Business segments
Exhibit 64: Merck – Organizational developments
Exhibit 65: Merck – Geographic focus
Exhibit 66: Merck – Segment focus
Exhibit 67: Merck – Key offering
Exhibit 68: Merck – Key customers
Exhibit 69: Novartis – Vendor overview
Exhibit 70: Novartis – Business segments
Exhibit 71: Novartis – Organizational developments
Exhibit 72: Novartis – Geographic focus
Exhibit 73: Novartis – Segment focus
Exhibit 74: Novartis – Key offerings
Exhibit 75: Novartis – Key customers
Exhibit 76: Pfizer – Vendor overview
Exhibit 77: Pfizer – Business segments
Exhibit 78: Pfizer – Organizational developments
Exhibit 79: Pfizer – Geographic focus
Exhibit 80: Pfizer – Segment focus
Exhibit 81: Pfizer – Key offerings
Exhibit 82: Pfizer – Key customers


【レポート販売概要】

■ タイトル:尿失禁治療薬の世界市場2019-2023
■ 英文:Global Urinary Incontinence Therapeutics Market 2019-2023
■ 発行日:2018年10月30日
■ 調査会社:Technavio
■ 商品コード:IRTNTR30102
■ 調査対象地域:グローバル、アジア、北米、ヨーロッパ(EMEA)
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。